BMC Cancer最新文献

{"title":"Vasectomy and prostate cancer risk: a pooled of cohort studies and Mendelian randomization analysis.","authors":"Li Wang, Si-Yu Chen, Shun Wan, Kun-Peng Li, Xiao-Ran Li, Li Yang","doi":"10.1186/s12885-025-13750-8","DOIUrl":"https://doi.org/10.1186/s12885-025-13750-8","url":null,"abstract":"<p><strong>Background: </strong>The relationship between vasectomy and the risk of prostate cancer (PCa) remains unclear, with observational studies reporting inconsistent results. To clarify this ambiguity, we embarked on a comprehensive investigation comprising both a meta-analysis and a Mendelian randomization (MR) study. This dual approach aimed to thoroughly examine not only the association but also the causality between undergoing a vasectomy and the subsequent risk of PCa.</p><p><strong>Methods: </strong>Our systematic review meticulously examined cohort studies published until January 2024, employing a random effects model for the computation of relative risks (RR) and their 95% confidence intervals (CI). For MR Analysis, we leveraged aggregated data from the IEU Open GWAS database, investigating the correlation between genetic predisposition to vasectomy and PCa. We chose single nucleotide polymorphisms (SNPs) of European descent as instrumental variables (IVs) for this analysis. The primary method for calculating the odds ratios (ORs) and their 95% CIs was inverse variance weighting (IVW). Through sensitivity analysis, we confirmed the robustness of our findings.</p><p><strong>Results: </strong>Our investigation synthesized data from 19 cohort studies, encompassing over four million participants. The combined analysis revealed a statistically significant link between vasectomy and an elevated risk of PCa across any grade (RR = 1.09; 95%CI: 1.05-1.14; P = 0.001; I² = 83.3%). This association was observed for both localized PCa (RR = 1.08; 95% CI: 1.04-1.13; P < 0.001; I² = 48.8%) and advanced PCa (RR = 1.07; 95% CI: 1.01-1.13; P = 0.016; I² = 0%). Nonetheless, the discovery cohort MR Analysis indicated no genetic causal link between vasectomy and PCa (OR = 0.067; 95%CI = 0.002-1.535; P = 0.09). A validation set in the Finnish population confirmed the robustness of the results. This conclusion remained consistent even after controlling for variables such as prostate-specific antigen (PSA) testing and body mass index (BMI), suggesting that while a statistical association exists, the genetic evidence does not support a causal relationship.</p><p><strong>Conclusion: </strong>The cumulative analysis indicates a possible elevated risk of PCa in patients who have had a vasectomy. However, MR Analysis has not confirmed a direct causal link between vasectomy and PCa. This suggests that the association observed may not stem from direct causation, allowing for the continued consideration of vasectomy as a viable long-term contraceptive choice. Further research is imperative to uncover any factors that could potentially link vasectomy to an increased risk of prostate cancer, aiming to provide a more comprehensive understanding of the implications.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"332"},"PeriodicalIF":3.4,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of combining cetuximab with the traditional chemotherapy regimens on clinical effectiveness in metastatic colorectal cancer: a systematic review and meta-analysis.","authors":"Marryam Azeem, Anees Ur Rehman, Saba Rasheed, Aleena Shahzad, Muhammad Hamza Javed, Qurratul Ain Jamil, Hidayah Karuniawati, Saleh Karamah Al-Tamimi","doi":"10.1186/s12885-025-13515-3","DOIUrl":"https://doi.org/10.1186/s12885-025-13515-3","url":null,"abstract":"<p><strong>Background: </strong>Metastatic colorectal cancer (mCRC) poses a high rate of morbidity and mortality despite various treatment advances. Cetuximab, an anti-EGFR, has shown promising efficacy in improving outcomes when combined with chemotherapy. Understanding its efficacy is essential for optimizing treatment strategies in mCRC. This systematic review and meta-analysis aims to evaluate the effectiveness of combining cetuximab with chemotherapy in mCRC.</p><p><strong>Methods: </strong>PubMed and Google Scholar were systematically searched following the benchmarks indicated by PRISMA. The primary outcomes of the study were progression-free survival (PFS) and overall survival (OS). Statistical analyses were executed using Stata version 16.</p><p><strong>Results: </strong>The meta-analysis encompassed 25 studies involving 3788 mCRC patients. The median age spans from 18 to 77 years. The cetuximab plus chemotherapy exhibited a higher PFS and OS with a significant difference (PFS: HR = 0.79, 95% CI = 0.63-0.96, p < 0.01, I² = 38% and OS: HR = 0.78, 95% CI = 0.60-0.91, p < 0.01, I² = 47%) compared to the control group. Subgroup analysis based on randomized controlled trials demonstrated consistent treatment effects for PFS (HR = 0.77, 95% CI = 0.62-0.93) and OS (HR = 0.76, 95% CI = 0.61-0.88) in the cetuximab treatment group.</p><p><strong>Conclusions: </strong>Combining cetuximab with chemotherapy offers a potential benefit in improving survival outcomes for metastatic colorectal cancer patients, as indicated by this study. These results suggest that cetuximab may be a valuable addition to mCRC treatment strategies, warranting further clinical investigation and integration into standard care.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"331"},"PeriodicalIF":3.4,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic changes in immune repertoire profiles in patients with stage III unresectable non-small cell lung cancer during consolidation treatment with immunotherapy.","authors":"Nareenart Iemwimangsa, Dulyathat Anantaya, Songporn Oranratnachai, Thanaporn Thamrongjirapat, Putthapoom Lumjiaktase, View-Hune Teoh, Khantong Khiewngam, Nanamon Monnamo, Pimtip Sanvarinda, Pimpin Incharoen, Angkana Charoenyingwattan, Insee Sensorn, Thitiya Dejthevaporn, Ekaphop Sirachainan, Wasun Chantratita, Thanyanan Reungwetwattana, Narumol Trachu","doi":"10.1186/s12885-025-13716-w","DOIUrl":"https://doi.org/10.1186/s12885-025-13716-w","url":null,"abstract":"<p><strong>Background: </strong>One-year of immune checkpoint inhibitor (ICI) treatment after concurrent chemoradiation (CCRT) in unresectable stage III non-small cell lung cancer (NSCLC) is a standard of care. The precise predictive biomarkers are under investigations either immunological markers or clinical characteristics. Here, we explored immune repertoire of T cell receptor β-chain (TCRβ) during ICI treatment.</p><p><strong>Methods: </strong>During August 2019 and September 2021, stage III NSCLC, post CCRT patients from Ramathibodi Hospital was enrolled. All patients were treated by durvalumab after CCRT. Blood samples were collected together with clinical data and tumor assessment every 3-4 months until disease progression or discontinuation of treatment due to adverse events. CDR3 region and TCRΒ polymorphisms was explored by RNA sequencing using Next-Generation Sequencing (NGS) TCR beta short-read assay. Bioinformatic analysis was performed to analyze clonal diversity, TCR convergence frequency and the Shannon diversity from each timepoint. Immune repertoire and clinical correlation were explored using Spearman's correlation and Pearson's correlation. RStudio software version 2021 build 372 was used for analyses. A significance level was at P < 0.05.</p><p><strong>Results: </strong>Forty-four blood samples from 12 patients were analyzed. Mean duration of durvalumab treatment was 284 days. After durvalumab treatment, increasing of TCR convergence frequency was found compared to baseline (R = 0.36). Interestingly, it was also significantly higher in non-progressive disease (non-PD) patients compared with progressive disease (PD) patients (P = 0.011). Furthermore, Shannon diversity was higher increasing in PD patients compared with non-PD patients. Taken together, our study found that increasing of TCR convergence with less T-cell diversity in non-PD patients probably demonstrated a T cell-specific clonal expansion response to durvalumab treatment in this population.</p><p><strong>Conclusions: </strong>TCRβ repertoire is the potential biomarker for predicting durvalumab treatment response in post CCRT stage III NSCLC patients. However, a larger cohort with long-read assay should be explored.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"333"},"PeriodicalIF":3.4,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: findings from the global burden of disease study 2021.","authors":"Yingying Li, Wenfu Song, Ping Gao, Xutao Guan, Bing Wang, Liutong Zhang, Yaxuan Yao, Yaqiong Guo, Yi Wang, Shiqing Jiang, Shiling Sun","doi":"10.1186/s12885-025-13741-9","DOIUrl":"10.1186/s12885-025-13741-9","url":null,"abstract":"<p><strong>Background: </strong>Female breast cancer, cervical cancer, uterine cancer, and ovarian cancer (FBCUO) pose a significant threat to global public health. Data from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2021 provide critical insights that can guide the understanding and management of these cancers. Our study aims to offer comprehensive global, regional, and national estimates of the FBCUO cancer burden and its attributable risk factors from 1990 to 2021, as well as project future incidence trends up to 2050. These projections are essential for developing targeted prevention and control strategies, thereby informing more effective public health interventions.</p><p><strong>Methods: </strong>Incidence, age-standardised incidence rate (ASIR), deaths, age-standardised mortality rate (ASMR), disability-adjusted life years (DALYs), age-standardised rate of DALYs (ASDR), and the burden due to risk factors associated with FBCUO cancer were analysed from 1990 to 2021, and the Bayesian APC model was utilized for forecasting future epidemiological trajectories. All statistical analyses were performed using Join-point software (version 4.9.1.0).</p><p><strong>Results: </strong>Between 1990 to 2021, the global incidence, death, and DALYs, of female breast, cervical, uterine and ovarian cancer both to varying degrees of elevation. However, the ASMR and ASDR both showed a decreasing trend for FBCUO cancer. In 2021, diet high in red meat was a major risk factor for female breast cancer DALYs, but the attributable ASDR for diet high in red meat decreased from 1990 to 2021. Unsafe sex was the leading risk factor for cervical cancer DALYs, high body-mass index were the leading risk factor for uterine cancer and ovarian cancer. Projections indicate a global increase in the total number of female breast cancer and ovarian cancer cases from 2021 to 2050. In contrast, both cervical cancer and uterine cancer are expected to show downward trends over the same period.</p><p><strong>Conclusions: </strong>The burden attributable to FBCUO cancers has increased significantly in female populations from 1990 to 2021, underscoring the urgent need for targeted measures to mitigate this trend. Meanwhile, Annual Percentage Change (APC) analysis indicates that the age-standardized incidence rates (ASIR) for female breast and ovarian cancers may continue to rise from 2022 to 2050. This projection highlights the importance of timely interventions to address these growing challenges.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"330"},"PeriodicalIF":3.4,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term outcomes of laparoscopic D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in distal gastric cancer patients with high body mass index.","authors":"Yong Sun, Lei Hou, Enhong Zhao","doi":"10.1186/s12885-025-13732-w","DOIUrl":"10.1186/s12885-025-13732-w","url":null,"abstract":"<p><strong>Background: </strong>The technical challenges and safety issues involving laparoscopic D2 lymphadenectomy plus complete mesogastric excision (D2 + CME) for high body mass index (BMI) patients are still unknown. This study was conducted to compare the short-term outcomes of laparoscopic D2 + CME and D2 lymphadenectomy in distal gastric cancer patients of different BMI status.</p><p><strong>Methods: </strong>We retrospectively analyzed the data of patients with gastric cancer who underwent laparoscopic-assisted distal gastrectomy (LADG) at our center between 2019 June and 2023 September. Patients who underwent traditional laparoscopic D2 lymphadenectomy were divided into the D2 group, while patients undergoing laparoscopic D2 + CME were divided into the D2 + CME group. In each group, patients were further subdivided based on their BMI into the high BMI group (H-BMI, BMI ≥ 25) and normal BMI (N-BMI, BMI<25) group. A comparison was made between the characteristics of patients and their short-term outcomes in the two subgroups, respectively. Propensity score matching (PSM) at 1:1 ratio was performed to further assess the short-term outcomes of patients with high BMI in two groups.</p><p><strong>Results: </strong>AII the qualified patients were divided into the D2 group (n = 329) and D2 + CME group (n = 261). In the subgroup analysis of early surgical outcomes of the D2 group, the high BMI subgroup had longer surgery time (p = 0.007), more blood loss (p = 0.006) and longer time to first flatus (p = 0.001), compared to the normal BMI subgroup. Conversely, in the D2 + CME group, significant differences were not observed in early surgical outcomes between the two subgroups(p > 0.05). PSM yielded 44 high BMI patients with comparable baseline characteristics into the A group and the B group. Compared to the A group, patients with high BMI in the B group who received laparoscopic D2 + CME had shorter surgery time(p<0.001), less blood loss(p = 0.004), more retrieved lymph nodes (LNs) (p = 0.016). No statistical differences were observed in terms of the first flatus time, pT stage, pN stage, pathological stage(pStage), vascular invasion, postoperative complications, or postoperative hospital stay(p > 0.05).</p><p><strong>Conclusion: </strong>Our findings suggest the high BMI status had a significant impact on the early surgical results of laparoscopic conventional D2 lymphadenectomy. However, laparoscopic D2 + CME was unaffected by a high BMI. In addition, patients with high BMI benefit more from laparoscopic D2 + CME in terms of short-term outcomes. Laparoscopic D2 + CME is a recommended technique for distal gastric cancer patients with high BMI, which deserves further study and promotion.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"329"},"PeriodicalIF":3.4,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone tumors: a systematic review of prevalence, risk determinants, and survival patterns.","authors":"Hasan Hosseini, Sina Heydari, Kiavash Hushmandi, Salman Daneshi, Rasoul Raesi","doi":"10.1186/s12885-025-13720-0","DOIUrl":"10.1186/s12885-025-13720-0","url":null,"abstract":"<p><strong>Background: </strong>Though relatively rare, bone tumors significantly impact patient health and treatment outcomes.</p><p><strong>Objective: </strong>This systematic review analyzes the incidence, types, survival rates, and risk factors associated with bone tumors, including both benign and malignant forms.</p><p><strong>Methods: </strong>This systematic review was conducted using the keywords \"bone tumors,\" \"epidemiology,\" \"benign bone tumors,\" \"malignant bone tumors,\" \"osteosarcoma,\" \"Ewing sarcoma,\" \"chondrosarcoma,\" \"risk factors,\" and \"survival\" in electronic databases including PubMed, Scopus, Web of Science, and Google Scholar from 2000 to 2024. The search strategy was based on the PRISMA statement. Finally, 9 articles were selected for inclusion in the study.</p><p><strong>Results: </strong>The systematic review highlights that primary bone tumors can be classified into benign and malignant types, with osteosarcoma being the most prevalent malignant form, particularly among adolescents and young adults. The epidemiology of bone tumors is influenced by factors such as age, gender, geographic location, and genetic predispositions. Recent advancements in imaging techniques have improved the detection of these tumors, contributing to an increasing recognition of their prevalence. Data shows that the limited-duration prevalence of malignant bone tumors has increased significantly. This increase is from 0.00069% in 2000 to 0.00749% in 2018, indicating an increasing recognition and diagnosis of these rare tumors over time. Survival rates vary significantly by tumor type, with approximately 50-60% for osteosarcoma and around 70% for Ewing's sarcoma, though these rates decrease with metastasis. Key risk factors identified include genetic predispositions such as Li-Fraumeni syndrome and TP53 mutations, environmental exposures like radiation, and growth patterns related to height.</p><p><strong>Conclusion: </strong>The review highlights the importance of early diagnosis and treatment intervention, as survival rates are significantly better for patients with localized disease compared to those with metastatic conditions. The observed variations in survival rates across different tumor types underscore the need for tailored treatment strategies. Key risk factors include genetic predispositions and environmental exposures, highlighting the need for targeted screening and ongoing research to enhance diagnostic accuracy and treatment strategies.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"321"},"PeriodicalIF":3.4,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quercetin affects apoptosis and autophagy in pediatric acute myeloid leukaemia cells by inhibiting PI3K/AKT signaling pathway activation through regulation of miR-224-3p/PTEN axis.","authors":"Jing Sun, Min Sha, Jing Zhou, Yun Huang","doi":"10.1186/s12885-025-13709-9","DOIUrl":"10.1186/s12885-025-13709-9","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to investigate the mechanism by which quercetin (Que) affects apoptosis and autophagy in pediatric acute myeloid leukaemia (AML) cells by inhibiting the activation of the PI3K/AKT signaling pathway through the regulation of the miR-224-3p/PTEN axis.</p><p><strong>Methods: </strong>Blood samples were collected from AML children and healthy volunteers. miR-224-3p and PTEN expression levels were measured. AML cells were pre-treated with Que. MiR-224-3p and PTEN expression levels in AML cells were altered via plasmid transfection. After intervention, PI3K/AKT phosphorylation, AML cell proliferation and apoptosis, concentrations of interleukin-1 β (IL-1β) and tumor necrosis factor-α (TNF-α) in AML cell culture supernatant, apoptosis-related genes Bax and Bcl-2, and autophagy markers LC3-I and LC3-II were tested. The targeting relationship between miR-224-3p and PTEN was identified.</p><p><strong>Results: </strong>MiR-224-3p expression was elevated in AML children, while PTEN was decreased. Que was available to accelerate AML cell apoptosis and restrain its autophagy. Que inhibited miR-224-3p expression and promoted PTEN expression. Upregulating miR-224-3p or downregulating PTEN weakened the effect of Que on AML cell apoptosis and autophagy. MiR-224-3p negatively modulated PTEN expression. Up-regulation of PTEN reversed the effects of up-regulation of miR-224-3p on apoptosis and autophagy in AML cells. In addition, Que inhibited PI3K/AKT signaling pathway activation, while up-regulation of miR-224-3p or down-regulation of PTEN could attenuate the inhibitory effect of Que on PI3K/AKT signaling pathway. Moreover, up-regulation of PTEN reversed the effect of up-regulation of miR-224-3p on the PI3K/AKT signaling pathway.</p><p><strong>Conclusion: </strong>Que affects apoptosis and autophagy in pediatric AML cells by inhibiting PI3K/AKT signaling pathway activation through regulation of miR-224-3p/PTEN axis.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"318"},"PeriodicalIF":3.4,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small non-coding RNA profiling in patients with non-muscle invasive bladder cancer.","authors":"Jiajia Cai, Zeqin Yan, Yadi Zhong, Yuqing Li, Jianxu Huang, Huijuan Hu, Yingrui Li, Hu Fang, Song Wu","doi":"10.1186/s12885-025-13672-5","DOIUrl":"10.1186/s12885-025-13672-5","url":null,"abstract":"<p><p>The intricate regulatory roles of small non-coding RNAs (sncRNAs), including PIWI-interacting RNAs (piRNAs) and microRNAs (miRNAs), have been increasingly recognized in the modulation of cellular functions and are associated with the pathogenesis of various diseases, notably cancer. However, the specific dysregulation patterns of sncRNAs in non-muscle-invasive bladder cancer (NMIBC) have yet to be fully delineated, highlighting a significant gap in our current understanding. To elucidate the expressional dynamics of sncRNAs for patients with NMIBC, we characterized the profile of piRNAs and miRNAs by next-generation sequencing. We identified the differentially expressed sncRNAs between tumor and paracancerous tissues and characterized their distribution along the genome. We further revealed a set of immune-related piRNAs and dysregulated miRNAs that might be associated with NMIBC pathogenesis. Differentially expressed piRNAs were predominantly localized at the long arms of chromosomes 13, 1, and 6. Notably, the targets of specific piRNAs, including piR-hsa-2215234, piR-hsa-105306, piR-hsa-102066, and piR-hsa-236465, show significant associated with antigen processing and presentation pathway. Additionally, differentially expressed miRNAs are mainly located on chromosome 14 and their target genes tend to be involved in cancer-related pathways, suggesting their potential regulatory roles in NMIBC. Collectively, this study revealed the global sncRNA dysregulation in NMIBC, and the identified sncRNAs are implicated in the modulation of both immune and cancer pathways, suggesting their contribution to the pathogenesis and potential targets for immunotherapy.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"319"},"PeriodicalIF":3.4,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LINC00657 exhibits oncogenic properties in prostate cancer and may serve as a prognostic biomarker in cancer.","authors":"Yaoan Wen, Shuyuan Zhan, Shenfan Wang, Longjie Yang, Siqi Yang, Song Zheng","doi":"10.1186/s12885-025-13746-4","DOIUrl":"10.1186/s12885-025-13746-4","url":null,"abstract":"<p><strong>Background: </strong>The prognostic significance of long non-coding RNA LINC00657 remains ambiguous, and its role in prostate cancer (PCa) is not well characterized. This study aims to conduct a meta-analysis to clarify the clinical implications of LINC00657 in various malignancies and to assess its impact on PCa.</p><p><strong>Methods: </strong>A systematic search was conducted across PubMed, Embase, and Web of Science to identify relevant studies. Hazard ratios (HR) with 95% confidence intervals (95% CI) and associated clinicopathological factors were extracted. Subgroup analyses were performed based on sample size and cancer type. The expression levels of LINC00657 in PCa tissues were analyzed using the GTEx and TCGA databases. Additionally, transwell, wound healing, and EdU assays were utilized to evaluate cell migration and proliferation. An in vivo xenograft model was also employed to investigate the role of LINC00657 in PCa.</p><p><strong>Results: </strong>The meta-analysis included 11 eligible studies comprising 1,226 patients. Our findings indicate that overexpression of LINC00657 is significantly correlated with poor overall survival (HR = 2.09, 95% CI: 1.26-2.91), distant metastasis (OR = 2.15, 95% CI: 1.34-3.46), and advanced TNM staging (OR = 3.07, 95% CI: 1.22-7.74) across malignancies. Analysis of the TCGA and GTEx databases, corroborated by experiments in cell lines, revealed that LINC00657 is overexpressed in PCa. Furthermore, knockdown of LINC00657 resulted in reduced migration and invasion of PCa cells in vitro, as well as inhibited cell growth both in vitro and in vivo.</p><p><strong>Conclusion: </strong>The findings suggest that LINC00657 plays an oncogenic role in PCa and could be a valuable indicator of poor prognosis in cancer.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"314"},"PeriodicalIF":3.4,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Barriers to cervical cancer screening among immigrant Yemeni women in Malaysia.","authors":"Eshrak Ba-Alawi, Meram Azzani, Nahlah Abduljaleel Alsaidi, Wahib M Atroosh, Bilquis Taher Anaam, Dalila Roslan, Rola Ali-Saeed, Sarah Noman","doi":"10.1186/s12885-025-13748-2","DOIUrl":"10.1186/s12885-025-13748-2","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"320"},"PeriodicalIF":3.4,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}